<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226771</url>
  </required_header>
  <id_info>
    <org_study_id>Eu-nr 2010-018332-41</org_study_id>
    <secondary_id>2010-018332-41</secondary_id>
    <nct_id>NCT01226771</nct_id>
  </id_info>
  <brief_title>Ribavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1</brief_title>
  <acronym>RibaC</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Swedish Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, parallel group, multicenter pilot study evaluating the&#xD;
      efficacy and safety of alternative dosing of ribavirin vs. standard of care dosing in&#xD;
      combination with peginterferon alpha-2a in interferon naïve patients with chronic hepatitis c&#xD;
      genotype 1 infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to demonstrate the efficacy and safety of (A) 2 weeks&#xD;
      of high dose of ribavirin (&quot;loading&quot;, ≥26 mg/kg/day for 14 days followed by ≥13 mg/kg/day)&#xD;
      followed by concentration targeted (≥ 2.5 mg/L (10.25 μmol/L) 28 days after initiation of&#xD;
      ribavirin therapy) dosing of ribavirin vs. (B) 4 weeks of ribavirin dosing before initiation&#xD;
      of PEG-interferon dosing (&quot;priming&quot;, ≥13 mg/kg/day) followed by concentration targeted (≥ 2.5&#xD;
      mg/L (10.25 μmol/L) 28 days after initiation of ribavirin therapy) dosing of ribavirin in&#xD;
      combination with peginterferon alpha-2a in interferon naïve patients with chronic hepatitis C&#xD;
      (CHC) virus genotype 1 infection as compared to (C) standard-of-care dosing of ribavirin (≥13&#xD;
      mg/kg/day without monitoring of ribavirin concentrations) in combination with peginterferon&#xD;
      alpha-2a.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The early virological response as measured by decline in HCV-RNA during the first 12 weeks of peginterferon alpha-2a and ribavirin therapy in the three study arms.</measure>
    <time_frame>The first 12 weeks of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>VRVR, RVR, cEVR, pEVR, SVR, and Relapse rates</measure>
    <time_frame>Throughout the treatment period including 24 weeks post completion of therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group A (&quot;Loading&quot;)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (&quot;Priming&quot;)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (&quot;Standard-of-Care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin &quot;loading&quot; dose given</intervention_name>
    <description>PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks</description>
    <arm_group_label>Group A (&quot;Loading&quot;)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>&quot;Priming&quot; dose of ribavirin given</intervention_name>
    <description>Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks</description>
    <arm_group_label>Group B (&quot;Priming&quot;)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group C (&quot;Standard-of-Care&quot;)</intervention_name>
    <description>PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks</description>
    <arm_group_label>Group C (&quot;Standard-of-Care)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Male and female patients ≥18 years of age&#xD;
&#xD;
          -  Serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test&#xD;
&#xD;
          -  Serum HCV-RNA ≥15 IU/mL.&#xD;
&#xD;
          -  HCV genotype 1 infection confirmed within the past 2 years preceding the initiation of&#xD;
             test drug dosing.&#xD;
&#xD;
          -  Compensated liver disease (Child-Pugh Grade A clinical classification)&#xD;
&#xD;
          -  Patients with cirrhosis or transition to cirrhosis must have an abdominal ultrasound,&#xD;
             CT scan, or MRI scan without evidence of hepatocellular carcinoma and a serum AFP ≤100&#xD;
             ng/mL within 2 months of randomization&#xD;
&#xD;
          -  Negative urine or blood pregnancy test (for women of childbearing potential)&#xD;
             documented within the 24-hour period prior to the first dose of study drug&#xD;
&#xD;
          -  All fertile males and females receiving ribavirin must be using effective&#xD;
             contraception during treatment and during 4 months for female patients / 7 months for&#xD;
             male patients after end of treatment&#xD;
&#xD;
          -  Subject must weigh between 45 and 105 kg at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with ongoing pregnancy or breast feeding&#xD;
&#xD;
          -  IFN/ peg-interferon with or without ribavirin therapy at any previous time&#xD;
&#xD;
          -  Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment&#xD;
             (including supraphysiologic doses of steroids and radiation) *6 months prior to the&#xD;
             first dose of study drug&#xD;
&#xD;
          -  Any investigational drug ≤6 weeks prior to the first dose of study drug.&#xD;
&#xD;
          -  HCV genotype 2, 3, 4, 5, 6, or 7 infection.&#xD;
&#xD;
          -  Positive test at screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab, anti-HIV Ab&#xD;
&#xD;
          -  Evidence of a medical condition associated with chronic liver disease other than HCV&#xD;
             (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver&#xD;
             disease, toxin exposures)&#xD;
&#xD;
          -  History or other evidence of decompensated liver disease&#xD;
&#xD;
          -  Neutrophil count &lt;1500 cells/mm3 or platelet count &lt;90,000 cells/mm3 at screening&#xD;
&#xD;
          -  Serum creatinine level &gt;2 mg/dl (&gt;124 µmol/L) or creatinine clearance ≤50 ml/minute at&#xD;
             screening&#xD;
&#xD;
          -  Severe psychiatric disease, especially depression, as judged by the treating&#xD;
             physician.&#xD;
&#xD;
          -  History of a severe seizure disorder or current anticonvulsant use&#xD;
&#xD;
          -  History of immunologically mediated disease, severe chronic pulmonary disease&#xD;
             associated with functional limitation, severe cardiac disease, major organ&#xD;
             transplantation or other evidence of severe illness, malignancy, or any other&#xD;
             conditions which would make the patient, in the opinion of the investigator,&#xD;
             unsuitable for the study&#xD;
&#xD;
          -  Thyroid dysfunction not adequately controlled (TSH and T4 levels out of normal range)&#xD;
&#xD;
          -  Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration) or clinically&#xD;
             relevant ophthalmological disorder due to diabetes mellitus or hypertension&#xD;
&#xD;
          -  Evidence of drug abuse (including excessive alcohol consumption) in accordance with&#xD;
             local therapeutic traditions.&#xD;
&#xD;
          -  Inability or unwillingness to provide informed consent or abide by the requirements of&#xD;
             the study&#xD;
&#xD;
          -  Male partners of women who are pregnant&#xD;
&#xD;
          -  Ηemoglobin &lt;12 g/dL in women or &lt;13 g/dL in men at screening.&#xD;
&#xD;
          -  Any patient with an increased baseline risk for anemia (e.g. thalassemia major,&#xD;
             spherocytosis, history of GI bleeding, etc) or for whom anemia would be medically&#xD;
             problematic coagulopathia.&#xD;
&#xD;
          -  Patients with documented or presumed coronary artery disease or cerebrovascular&#xD;
             disease should not be enrolled if, in the judgment of the investigator, an acute&#xD;
             decrease in hemoglobin by up to 4 g/dL (as may be seen with ribavirin therapy) would&#xD;
             not be well-tolerated&#xD;
&#xD;
          -  Evidence of allergy to PEG-IFN or ribavirin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept. of Infectious Diseases</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>October 21, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2010</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis V virus</keyword>
  <keyword>genotype 1</keyword>
  <keyword>ribavirin</keyword>
  <keyword>interferon</keyword>
  <keyword>Alternative ribavirin dosing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

